Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study

Area of Science:

• Pharmacogenetics
• Pediatric Psychiatry
• Clinical Pharmacology

Background:

• Selective serotonin reuptuptake inhibitors (SSRIs) are a common treatment for pediatric anxiety disorders like generalized anxiety disorder (GAD).
• Predicting the efficacy and tolerability of SSRIs in adolescents can be challenging.
• This study investigates escitalopram's effectiveness and safety in adolescents with GAD.

Purpose of the Study:

• To evaluate the efficacy and tolerability of escitalopram in adolescents diagnosed with GAD.
• To assess the impact of genetic variants (HTR2A, SLC6A4) and CYP2C19 phenotypes on treatment response.
• To examine the effect of CYP2C19 phenotype on escitalopram pharmacokinetics.

Main Methods:

• Adolescents with GAD received either escitalopram (up to 20 mg/d) or placebo for 8 weeks.
• Efficacy was measured by changes in Pediatric Anxiety Rating Scale (PARS) and Clinical Global Impressions (CGI) scores.
• Pharmacokinetic parameters (Cmax, AUC0-24) of escitalopram and its metabolite were analyzed in relation to CYP2C19 phenotypes.

Main Results:

• Escitalopram demonstrated significant superiority over placebo in reducing PARS and CGI scores (P = .005).
• Increased CYP2C19 metabolism was associated with reduced escitalopram Cmax (P = .07) and AUC0-24 (P < .05).
• No significant differences in vital signs, QT interval, or adverse events were observed between groups.

Conclusions:

• Escitalopram is an effective treatment for reducing anxiety symptoms in adolescents.
• Pharmacogenetic variables, particularly CYP2C19 metabolism, influence escitalopram's pharmacokinetic profile and treatment response.
• Considering CYP2C19 phenotype may be beneficial for optimizing escitalopram therapy in pediatric patients.